RegCell raises $44M to advance regulatory T cell therapies to human trials
RegCell, a biotech founded by Nobel laureate Shimon Sakaguchi, has closed a $44 million Series A financing round. The funds will support the company's move into clinical development for its regulatory T cell-based therapies, which aim to modulate the immune system. Sakaguchi's decades of research on Tregs underpin the platform, which targets autoimmune and inflammatory conditions.
The Series A round provides RegCell with capital to transition from preclinical research into human testing. The company's approach centers on regulatory T cells, a specialized immune population that helps restrain excessive immune responses. By harnessing these cells, the platform seeks to restore balance in patients whose immune systems mistakenly attack their own tissues.
The scientific foundation draws on Shimon Sakaguchi's decades of investigation into how regulatory T cells govern immune tolerance, work that earned him a Nobel Prize. Autoimmune and inflammatory disorders represent a large unmet medical need, and cell-based therapies that modulate immunity rather than broadly suppressing it could offer a more targeted treatment strategy than current options.
If these therapies prove safe and effective in trials, patients with chronic autoimmune and inflammatory conditions could gain a more precise treatment alternative with potentially fewer side effects than broad immunosuppressants. However, cell-based therapies are complex to manufacture and costly to deliver, which may limit accessibility even if approved. Success could reshape standard care for these conditions, while setbacks would slow the field. The ultimate societal impact depends on clinical outcomes over the coming years.